# Validation of NAD+ measurements for human clinical studies: multi-method inter-laboratory standardization

> **NIH NIH U01** · UNIVERSITY OF PENNSYLVANIA · 2024 · $1,001,704

## Abstract

Recent years have seen a surge of interest in the role of NAD in human disease and whether increasing NAD
with supplements such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) has therapeutic
value. However, our understanding of NAD and its metabolites in vivo is limited by technical barriers, a lack
of consensus on analytical techniques, and incomplete knowledge of the catabolic routes taken when NAD
breaks down under various stressed states. For many studies, blood and urine are the only samples available
to investigative teams. Whole blood contains NAD(P)(H), but poses important stability considerations for
handling and measurements. Serum and urine are relatively stable, but contain mostly catabolites of NAD,
which themselves carry implications for NAD metabolism in the rest of the body. Here we propose to take
advantage of a multidisciplinary team to develop and standardize methods for the analysis of NAD, as well
as NADH, NADP, NADPH that are suitable for human clinical trials. These include extensive validation and
testing of methods for determining the abundance of NAD(P)(H) in blood-derived samples and comparisons
between liquid chromatography-mass spectrometry-based assays, biochemical assays, and nuclear
magnetic resonance. We will also perform the first direct comparison of the two major magnetic resonance
spectroscopy (MRS) methods that have been used to detect NAD in intact tissues of living subjects. In years
1 and 2, we will focus primarily on method development, establishing techniques for the optimal handling and
storage of blood, as well as comparing the available methodology for NAD(P)(H) measurement. In years 3-5,
we will conduct a human clinical trial, examining NAD(P)(H) levels in tissues and blood, along with catabolite
levels in serum and urine before and after an intervention with nicotinamide riboside, thought to increase
whole blood and tissue NAD levels. By performing all of these assays in the same individuals, we will also
provide the first comprehensive assessment of the value of accessible bodily fluids for predicting tissue NAD
levels and, more broadly, for detecting physiologically relevant alterations in human NAD metabolism.
.

## Key facts

- **NIH application ID:** 10978752
- **Project number:** 1U01AG089107-01
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Joseph A. Baur
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,001,704
- **Award type:** 1
- **Project period:** 2024-08-15 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10978752

## Citation

> US National Institutes of Health, RePORTER application 10978752, Validation of NAD+ measurements for human clinical studies: multi-method inter-laboratory standardization (1U01AG089107-01). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10978752. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*